Comment on:Impact of switching from ranibizumab to aflibercept on the number of intravitreous injection and follow up visit in wet AMD:results of real-life ELU study  

作　　者：Dan Calugaru Mihai Calugaru 

机构地区：[1]Department of Ophthalmology,University of Medicine Cluj-Napoca 400014,Romania

出　　处：《International Journal of Ophthalmology(English edition)》2021年第7期1127-1128,共2页国际眼科杂志（英文版）

摘　　要：Dear Editor,The study by Queguiner et al[1]compared the number of follow up visits and intravitreal injections in 33 patients with wet age-related macular degeneration(AMD)treated initially with ranibizumab(Lucentis;Genentech,Inc.,South San Francisco,CA,USA;phase 1)and then switched to aflibercept(Eylea;Regeneron Pharmaceuticals Inc.

关 键 词：AMD IMPACT INJECTION 

分 类 号：TP3[自动化与计算机技术—计算机科学与技术]